To evaluate the safety and effectiveness of the SAPIEN 3 (Edwards Lifesciences, Irvine, California) transcatheter heart valve implantation (TAVI) in Chinese patients with symptomatic severe calcific aortic stenosis who are considered at high risk for surgical valve replacement.
Edwards SAPIEN 3 Transcatheter Heart Valve and Commander delivery system will be used for this study. A maximum of 60 patients with symptomatic severe calcific aortic stenosis requiring transcatheter aortic valve implantation (TAVI), who are considered high risk for surgical valve replacement who received a SAPIEN 3 THV.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
58
Edwards SAPIEN 3 Transcatheter Heart Valve is implanted using the Commander delivery system
Fuwai Hospital, CAMS&PUMC
Beijing, China
WestChina Hospital, Sichuan University
Chengdu, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
Zhongshan Hospital Fudan University
Shanghai, China
All-cause Mortality
All of the deaths that occurred in this population regardless of the cause.
Time frame: 30-days
Cardiovascular Mortality
All of the deaths that occurred in this population due to a cardiovascular issue.
Time frame: 30-days
Non-Cardiovascular Mortality
All of the deaths that occurred in this population due to a non-cardiovascular issue.
Time frame: 30-days
Number of Participants With a Stroke
Total number of participates with a stroke.
Time frame: 30-days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.